Cue Biopharma CEO files initial Form 3

Cue Biopharma, Inc. director and chief executive officer Shao-Lee Lin has filed an initial Form 3 statement of beneficial ownership with the SEC.

Rhea-AI Filing Summary

Cue Biopharma, Inc. director and chief executive officer Shao-Lee Lin has filed an initial Form 3 statement of beneficial ownership with the SEC. The filing does not list any individual transactions or derivative positions, serving instead as a baseline disclosure of insider status at the company.

Key Terms

Form 3, reporting person, derivative positions

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

""reportingPersons": [ { "name": "Lin Shao-Lee""

derivative positions financial

""derivativeSummary": [],"

Derivative positions are contracts that derive their value from an underlying asset—such as a stock, bond, currency or commodity—and include instruments like options, futures and swaps. Think of them as bets or insurance tied to an asset’s future price: they let investors amplify returns, hedge risk or take exposure without owning the asset directly, which can meaningfully increase potential gains, losses and volatility in a portfolio.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Cue Biopharma (CUE) disclose in this Form 3 filing?

Cue Biopharma reports that Shao-Lee Lin, its chief executive officer and a director, has filed a Form 3 initial statement of beneficial ownership. The filing lists no individual stock transactions or derivative holdings, establishing a starting point for future insider ownership reports.

Who is the reporting person in Cue Biopharma (CUE) Form 3?

The reporting person is Shao-Lee Lin, who serves as both a director and the chief executive officer of Cue Biopharma, Inc. This Form 3 identifies Lin as an insider whose future ownership changes will be reported on subsequent SEC forms.

Does Cue Biopharma’s Form 3 for Shao-Lee Lin show any stock transactions?

No, the Form 3 filing for Shao-Lee Lin shows no buy, sell, acquire, or dispose transactions. All transaction counts and share amounts are reported as zero, indicating this document is a baseline ownership statement rather than a record of recent trades.

Are any derivative securities reported for Shao-Lee Lin in the Cue Biopharma Form 3?

The filing indicates no derivative transactions or derivative positions for Shao-Lee Lin. The derivative transaction count and related share figures are all zero, and the derivative summary is empty, so no options, warrants, or similar instruments are disclosed here.

What does a neutral net buy/sell direction mean in Cue Biopharma’s Form 3?

The net buy/sell direction is shown as neutral because the filing reports no purchases or sales of Cue Biopharma shares. With all buy and sell counts at zero, the Form 3 functions purely as an initial ownership registration without signaling trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 04:00 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lin Shao-Lee

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/30/2026

3. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Shao-Lee Lin	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)